Clinical trial · no report yet · Phase 3
CAMBRIA-2
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
- NCT05952557 ↗
- Active not recruiting
- AstraZeneca
- 59 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 33 | |
| Podcasts | 17 | |
| X threads | 9 |
The trial
ClinicalTrials.gov- Official title
- CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Breast Cancer, Early Breast Cancer
- Interventions
- Camizestrant; Tamoxifen; Anastrozole; Letrozole; Exemestane; Abemaciclib
- Arms
- Arm A: standard endocrine therapy of investigator´s choice ± abemaciclib · Active comparator
- Arm B: camizestrant ± abemaciclib · Experimental
- Enrollment
- 5,511
- Primary outcomes
- Invasive breast cancer-free survival (IBCFS)
- Sponsor
- AstraZeneca with Austrian Breast & Colorectal Cancer Study Group
- Start
- Oct 5, 2023
- Primary completion
- Mar 4, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT05952557 · updated Aug 10, 2026
Publications
linked from the registry- Hamilton EP, Loibl S, Bachelot T, Gnant M, Niikura N, Park YH, Tolaney SM, Pistilli B, Rastogi P, Saini KS, Gioni I, Johnston S, Nunes R, Quintana A, Stuart M, Syta E, Walding A, Klinowska T, Mayer IA. CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer. Future Oncol. 2025 Mar;21(7):795-806. doi: 10.1080/14796694.2025.2459548. Epub 2025 Feb 27. PubMed 40017004